PE
VNDA icon

Point72 Europe’s Vanda Pharmaceuticals VNDA Stock Holding History

Point72 Europe’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.22K Buy
+245
New +$1.13K ﹤0.01% 688

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Point72 Europe's VNDA Position: Q3 2025 in Review

Point72 Europe opened a new position in Vanda Pharmaceuticals (VNDA) in Q3 2025: 245 shares worth $1.22K. The stake represents ﹤0.01% of the portfolio and ranks #688 among its holdings.

150 funds tracked by Wall St. Rank hold VNDA as of Q3 2025.

  • Point72 Europe held 245 shares of Vanda Pharmaceuticals worth $1.22K as of Q3 2025.
  • Vanda Pharmaceuticals was a new Point72 Europe position in Q3 2025.
  • Vanda Pharmaceuticals made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #688 holding.
  • 150 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.